COVID-19: Mylan to launch remdesivir in India at Rs 4,800 per 100 mg vial
Business | Jul 07, 2020, 08:43 AM ISTThe company joins domestic pharma firm Cipla and Hetero who have already received permission from the Drug Controller General of India (DCGI) to manufacture and market remdesivir for the treatment of COVID-19.